Theriva Biologics (TOVX) Long-Term Debt Repayments (2022 - 2025)

Theriva Biologics (TOVX) posted quarterly Long-Term Debt Repayments of $56000.0 for Q1 2025, up 180.0% quarter-over-quarter from $20000.0 in Q2 2023.

Theriva Biologics (TOVX) Long-Term Debt Repayments (2022 - 2025) Analysis & Trends

Theriva Biologics (TOVX) has reported Long-Term Debt Repayments for 3 consecutive years, with $56000.0 the latest figure, recorded in Q1 2025.

In Q1 2025, Long-Term Debt Repayments changed N/A year-over-year to $56000.0; the TTM figure through Mar 2025 stood at $56000.0 (changed N/A YoY), while the FY2024 annual figure was $67000.0, down 10.67% from the prior year.
Long-Term Debt Repayments improved to $56000.0 in Q1 2025 per TOVX's latest filing, from $20000.0 in the prior quarter.
Across five years, Long-Term Debt Repayments topped out at $1.4 million in Q1 2022 and bottomed at $20000.0 in Q2 2023.
Historically, Long-Term Debt Repayments has averaged $376750.0 across 3 years, with a median of $55500.0 in 2023.
On a YoY basis, Long-Term Debt Repayments climbed as much as 96.0% in 2023 and fell as far as 96.0% in 2023.
Theriva Biologics' Long-Term Debt Repayments stood at $1.4 million in 2022, then sank by 98.55% to $20000.0 in 2023, then jumped by 180.0% to $56000.0 in 2025.
Business Quant data shows TOVX's Long-Term Debt Repayments at $56000.0 in Q1 2025, $20000.0 in Q2 2023, and $55000.0 in Q1 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Repayments (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	17.05 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-10.01 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Theriva Biologics	10.64 Mn	10.64 Mn	-	-

Download Data